F. Rey

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Dosimetric impact of interfraction catheter movement and organ motion on MRI/CT guided HDR interstitial brachytherapy for gynecologic cancer.

Chang Chang, Boon-Keng Kevin Teo, Nayha Dixit, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

1362MO Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study

E. Antonarakis, E. Yu, M. Retz, 2022, Annals of Oncology.

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

R. Greil, S. Park, E. Antonarakis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.

R. Shapira-Frommer, G. Ke, S. Wildsmith, 2023, The Lancet. Oncology.